Exelixis (EXEL) Stock
NASDAQ · EXEL
58.36
Fundamentals
Market cap
$14.46B
Price / Earnings ratio
16.8x
Price / Sales ratio
6.0x
Price / Book ratio
7.9x
Return on assets
0.3%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Exelixis
Exelixis, Inc., a biotechnology company strong focus on discovering, developing, and commercializing innovative therapies for treating cancer, the company has made significant strides in advancing its pipeline of targeted oncology treatments. Exelixis is renowned for its flagship drug, Cabometyx (cabozantinib), which has gained approvals for various cancer indications, demonstrating the company's dedication to improving patients' lives. Through strategic collaborations, cutting-edge research, and a commitment to scientific excellence, Exelixis continues to be at the forefront of delivering breakthrough therapies in the fight against cancer.
SectorHealthcare
IndustryBiotechnology
Employees1,077
CEODr. Michael M. Morrissey Ph.D.
IPO DateApr 7, 2000
HeadquartersAlameda, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board | 1948 |
| Dr. Michael M. Morrissey Ph.D. | CEO, President & Director | 1961 |
| Mr. Christopher J. Senner | Executive VP & CFO | 1968 |
| Dr. Brenda J. Hefti J.D., Ph.D. | Senior VP & General Counsel | 1974 |
| Dr. Dana T. Aftab Ph.D. | Executive Vice President of Research & Development | 1964 |
| Mr. Patrick Joseph Haley M.B.A. | Executive Vice President of Commercial | 1976 |
| Dr. William Berg M.D. | Senior Vice President of Medical Affairs | — |
| Dr. Stefan Krauss Ph.D. | VP & Head of Business Development | — |
| Mr. Andrew Ross Peters | Senior Vice President of Strategy | — |
| Ms. Deborah Burke CPA | Senior VP of Finance & Controller | 1956 |
Fundamentals
Valuation
Market cap$14.46B
Price-to-sales ratio5.95
Price-to-book value7.86
Price-earnings ratio16.80
Return on Equity40.00%
Return on Sales0.42%
Return on Assets0.31%
PEG ratio2.27
Earnings Per Share
Earnings Per Share$3.29
Income Statement
Average volume2,025,898
EBITDA$1.06B
1 year high (52w)$59.72
1 year low (52w)$33.76
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



